Renato Giestas Serpa
Research Subjects
Renato Giestas Serpa has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Ramos Barbosa
Instituto de Cardiologia do Espírito Santo, Vitória, Brasil
7 shared publications - Tiago de Melo Jacques
School of Sciences of Santa Casa de Misericórdia de Vitoria, Vitória, ES, Brasil
5 shared publications Luiz Fernando Machado Barbosa
4 shared publicationsAfonso Dalmazio Souza Mario
3 shared publicationsFelipe Bortot Cesar
3 shared publications- Luiz Fernando Machado Barbosa
Cardiology, Hospital Santa Casa de Misericórdia de Vitória, Vitória, BRA
3 shared publications
Latest Publications
- Open Access
- 4 November 2020
- Published by MDPI AG in Preprints.org
Prognostic Value of the Six-Minute Walk Test in Heart Failure
Background: The 6-minute walk test (6MWT) is a simple and low-cost method that allows assessment of functional capacity in patients with heart failure (HF). However, the prognostic role of 6MWT in HF remains uncertain. Objectives: We aimed to evaluate the 6MWT as a predictor of mid-term adverse outcomes in patients with HF with mid-range and reduced ejection fraction. Methods: Prospective single-center cohort study that included patients with HF with an ejection fraction under 50% at a specialized outpatient HF service. Patients underwent the 6MWT on admission and were compared according to the distance walked: Group I walked ≥350 meters and group II <350 meters. The primary outcome was a composite of death from any cause or hospitalization for HF decompensation in one-year follow-up. Secondary outcomes were the components of the primary outcome in an isolated analysis. Results: Sixty patients were included, 43.3% male, with a mean age of 61.1 ± 12.9 years and ejection fraction 34.3 ± 10.1%. 52 patients (86.7%) were on guideline-directed triple therapy for HF. The average distance walked in the 6MWT was 395.1 ± 98.8 meters, with 40 patients (66.7%) in group I and 20 (33.3%) in group II. The primary outcome in groups I and II were, respectively, 15,0% and 35,0% (p=0.05). One-year mortality was 5.0% vs 15.0% (p=0.18) and the hospitalization rate was 10.0% vs 20.0% (p=0.28). Conclusions: There was no association of distance <350 meters in the 6MWT with the primary outcome in patients with HF. Despite the higher occurrence of outcomes in group II, the difference was not statistically significant in this analysis. On a selective basis, the 6MWT may be a useful tool for prognostic stratification in HF, if combined with other methods.
- 4 November 2020
- Published by MDPI AG in Preprints.org
Open AccessPrognostic Value of the Six-Minute Walk Test in Heart Failure
Background: The 6-minute walk test (6MWT) is a simple and low-cost method that allows assessment of functional capacity in patients with heart failure (HF). However, the prognostic role of 6MWT in HF remains uncertain. Objectives: We aimed to evaluate the 6MWT as a predictor of mid-term adverse outcomes in patients with HF with mid-range and reduced ejection fraction. Methods: Prospective single-center cohort study that included patients with HF with an ejection fraction under 50% at a specialized outpatient HF service. Patients underwent the 6MWT on admission and were compared according to the distance walked: Group I walked ≥350 meters and group II <350 meters. The primary outcome was a composite of death from any cause or hospitalization for HF decompensation in one-year follow-up. Secondary outcomes were the components of the primary outcome in an isolated analysis. Results: Sixty patients were included, 43.3% male, with a mean age of 61.1 ± 12.9 years and ejection fraction 34.3 ± 10.1%. 52 patients (86.7%) were on guideline-directed triple therapy for HF. The average distance walked in the 6MWT was 395.1 ± 98.8 meters, with 40 patients (66.7%) in group I and 20 (33.3%) in group II. The primary outcome in groups I and II were, respectively, 15,0% and 35,0% (p=0.05). One-year mortality was 5.0% vs 15.0% (p=0.18) and the hospitalization rate was 10.0% vs 20.0% (p=0.28). Conclusions: There was no association of distance <350 meters in the 6MWT with the primary outcome in patients with HF. Despite the higher occurrence of outcomes in group II, the difference was not statistically significant in this analysis. On a selective basis, the 6MWT may be a useful tool for prognostic stratification in HF, if combined with other methods.
- Open Access
- 2 November 2020
- Published by MDPI AG in Preprints.org
Prognostic Impact of Acute Kidney Injury on Decompensated Heart Failure
Introduction: Decompensated heart failure (HF) is a complex and debilitating syndrome, which constitutes a severe emergency condition with high morbidity and mortality. The kidneys play fundamental roles in the pathophysiology of HF and, in the context of decompensations, acute kidney injury (AKI) has a bilateral cause-and-effect relationship, which can significantly worsen prognosis. However, the interaction between AKI and decompensated HF is poorly understood. Objective: This study aimed to assess the occurrence of AKI in patients hospitalized due to decompensated HF and to analyze its prognostic impact during hospitalization. Methods: Prospective single-center observational study that included patients hospitalized due to decompensated HF in a tertiary-level teaching hospital, conducted between July 2017 and January 2020. Patients who developed AKI during hospitalization were compared with those who did not develop it, until hospital discharge or death. AKI was defined as a serum creatinine increase greater than or equal to 0.3 mg/dl in 48 hours, a 1.5-fold increase in baseline creatinine in seven days or urinary volume Results: Ninety-nine patients were included, with a mean age of 65.4 ± 14 years, of which 47 (47.5%) were male and 52 (52.5%) were female. Reduced ejection fraction was observed in 77.8% of patients, whilst 22.2% had a diagnosis of HF with preserved EF. The decompensation clinical classifications were: dry and warm = 7 (7.1%), wet and warm = 72 (72.7%), wet and cold = 15 (15.1%) and dry and cold = 5 (5.1%). The average left ventricular ejection fraction was 38.3% ± 15. AKI ocurred in 22 patients (22.2%). Comparison between patients who evolved with and without AKI showed higher mortality (36.4% vs 10.4%, p = 0.004) and the need for IMV (54.5% vs 13%, p = 0.0001) in the first group. There was no significant difference regarding the length of in-hospital stay (22.9 ± 19 vs 18.8 ± 16 days, p = 0.26). Conclusions: The occurrence of AKI was frequent in patients with decompensated HF requiring hospitalization, affecting approximately one out of five patients. This complication was significantly associated with increased mortality and the need for IMV during hospitalization.
- 2 November 2020
- Published by MDPI AG in Preprints.org
Open AccessPrognostic Impact of Acute Kidney Injury on Decompensated Heart Failure
Introduction: Decompensated heart failure (HF) is a complex and debilitating syndrome, which constitutes a severe emergency condition with high morbidity and mortality. The kidneys play fundamental roles in the pathophysiology of HF and, in the context of decompensations, acute kidney injury (AKI) has a bilateral cause-and-effect relationship, which can significantly worsen prognosis. However, the interaction between AKI and decompensated HF is poorly understood. Objective: This study aimed to assess the occurrence of AKI in patients hospitalized due to decompensated HF and to analyze its prognostic impact during hospitalization. Methods: Prospective single-center observational study that included patients hospitalized due to decompensated HF in a tertiary-level teaching hospital, conducted between July 2017 and January 2020. Patients who developed AKI during hospitalization were compared with those who did not develop it, until hospital discharge or death. AKI was defined as a serum creatinine increase greater than or equal to 0.3 mg/dl in 48 hours, a 1.5-fold increase in baseline creatinine in seven days or urinary volume Results: Ninety-nine patients were included, with a mean age of 65.4 ± 14 years, of which 47 (47.5%) were male and 52 (52.5%) were female. Reduced ejection fraction was observed in 77.8% of patients, whilst 22.2% had a diagnosis of HF with preserved EF. The decompensation clinical classifications were: dry and warm = 7 (7.1%), wet and warm = 72 (72.7%), wet and cold = 15 (15.1%) and dry and cold = 5 (5.1%). The average left ventricular ejection fraction was 38.3% ± 15. AKI ocurred in 22 patients (22.2%). Comparison between patients who evolved with and without AKI showed higher mortality (36.4% vs 10.4%, p = 0.004) and the need for IMV (54.5% vs 13%, p = 0.0001) in the first group. There was no significant difference regarding the length of in-hospital stay (22.9 ± 19 vs 18.8 ± 16 days, p = 0.26). Conclusions: The occurrence of AKI was frequent in patients with decompensated HF requiring hospitalization, affecting approximately one out of five patients. This complication was significantly associated with increased mortality and the need for IMV during hospitalization.
- Open Access
- 1 August 2018
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 64 (8) , 745-754
Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients – 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.
- 1 August 2018
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 64 (8) , 745-754
Open AccessAnthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
SUMMARY OBJECTIVES This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults. METHODS A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients. RESULTS After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients – 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies. CONCLUSIONS Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.
- Open Access
- 1 January 2018
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Acute Myocardial Infarction and Primary Percutaneous Coronary Intervention at Night Time
- 1 January 2018
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Open AccessAcute Myocardial Infarction and Primary Percutaneous Coronary Intervention at Night Time
- 1 January 2017
- Published by GN1 Sistemas e Publicacoes Ltd. in Salus Journal of Health Sciences
- Vol. 3 (3)
Associação entre qualidade de vida e mortalidade em pacientes com insuficiência cardíaca
- 1 January 2017
- Published by GN1 Sistemas e Publicacoes Ltd. in Salus Journal of Health Sciences
- Vol. 3 (3)
Associação entre qualidade de vida e mortalidade em pacientes com insuficiência cardíaca
- Open Access
- 1 January 2016
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Management of Pregnant Woman with Marfan Syndrome and Mechanical Aortic Valved Conduit
- 1 January 2016
- Published by Sociedade Brasileira de Cardiologia in International Journal of Cardiovascular Sciences
Open AccessManagement of Pregnant Woman with Marfan Syndrome and Mechanical Aortic Valved Conduit
- 1 January 2016
- Published by GN1 Sistemas e Publicacoes Ltd. in Salus Journal of Health Sciences
- Vol. 2 (2)
Análise das complicações da gestação de mulheres cardiopatas atendidas em um hospital de Vitória-ES
- 1 January 2016
- Published by GN1 Sistemas e Publicacoes Ltd. in Salus Journal of Health Sciences
- Vol. 2 (2)
Análise das complicações da gestação de mulheres cardiopatas atendidas em um hospital de Vitória-ES
- Open Access
- 1 January 2013
- Published by Elsevier in Revista Brasileira de Cardiologia Invasiva (English Version)
- Vol. 21 (3) , 295-298
Emergency Percutaneous Balloon Aortic Valvuloplasty in Critical Aortic Stenosis with Hemodynamic Instability
- 1 January 2013
- Published by Elsevier in Revista Brasileira de Cardiologia Invasiva (English Version)
- Vol. 21 (3) , 295-298
Open AccessEmergency Percutaneous Balloon Aortic Valvuloplasty in Critical Aortic Stenosis with Hemodynamic Instability
- Open Access
- 1 January 2013
- Published by Elsevier in Revista Brasileira de Cardiologia Invasiva (English Version)
- Vol. 21 (3) , 295-298
Valvuloplastia aórtica percutânea como medida salvadora na estenose aórtica crítica com instabilidade hemodinâmica
- 1 January 2013
- Published by Elsevier in Revista Brasileira de Cardiologia Invasiva (English Version)
- Vol. 21 (3) , 295-298
Open AccessValvuloplastia aórtica percutânea como medida salvadora na estenose aórtica crítica com instabilidade hemodinâmica